艾司科公司的CDI成像单元日前安装在美国德州的Inovar包装集团,这是艾司科公司售出的第5000台CDI和XPS曝光制版设备。对此,艾司科营销、行业关系和战略总监Jan De Roeck说:“这是艾司科和我们的柔版制版设备的一个了不起的里程碑。25年...艾司科公司的CDI成像单元日前安装在美国德州的Inovar包装集团,这是艾司科公司售出的第5000台CDI和XPS曝光制版设备。对此,艾司科营销、行业关系和战略总监Jan De Roeck说:“这是艾司科和我们的柔版制版设备的一个了不起的里程碑。25年来,我们一直致力于开发柔版制版设备,帮助客户缩短交货时间,最大限度地延长印刷机正常运行时间,并减少操作人员的互动,以提高整体效率。实现这一里程碑是对开发团队的创新以及那些已经在世界各地接受了这项技术的客户的证明。”展开更多
Clostridium difficile infection(CDI)is a major global public health concern,accounting for 15%-25%of antibiotic-associated diarrhea,50%-75%of antibiotic-associated colitis,and nearly all cases of pseudomembranous coli...Clostridium difficile infection(CDI)is a major global public health concern,accounting for 15%-25%of antibiotic-associated diarrhea,50%-75%of antibiotic-associated colitis,and nearly all cases of pseudomembranous colitis.Over the past decade,CDI outbreaks have become increasingly prevalent in North America and Europe,with rising incidence and mortality rates.In 2019,the Centers for Disease Control and Prevention(CDC)in the United States classified CDI as a“critical”public health threat in their report on antibiotic resistance threats[1].CDI incidence varies widely across countries,healthcare settings,and age groups,with cumulative incidence rates ranging from 1.12 to 631.80 per 100,000 people annually[2].As the epidemiology of CDI continues to evolve and our understanding of the disease advances,reassessing its burden remains essential.The Global Burden of Disease,Injury,and Risk Factors Study(GBD 2021)database offers new insights into this issue.展开更多
文摘艾司科公司的CDI成像单元日前安装在美国德州的Inovar包装集团,这是艾司科公司售出的第5000台CDI和XPS曝光制版设备。对此,艾司科营销、行业关系和战略总监Jan De Roeck说:“这是艾司科和我们的柔版制版设备的一个了不起的里程碑。25年来,我们一直致力于开发柔版制版设备,帮助客户缩短交货时间,最大限度地延长印刷机正常运行时间,并减少操作人员的互动,以提高整体效率。实现这一里程碑是对开发团队的创新以及那些已经在世界各地接受了这项技术的客户的证明。”
基金supported by the Beijing Natural Science Foundation(No.L202008)the Chinese Center for Disease Control and Prevention Foundation(No.201833).
文摘Clostridium difficile infection(CDI)is a major global public health concern,accounting for 15%-25%of antibiotic-associated diarrhea,50%-75%of antibiotic-associated colitis,and nearly all cases of pseudomembranous colitis.Over the past decade,CDI outbreaks have become increasingly prevalent in North America and Europe,with rising incidence and mortality rates.In 2019,the Centers for Disease Control and Prevention(CDC)in the United States classified CDI as a“critical”public health threat in their report on antibiotic resistance threats[1].CDI incidence varies widely across countries,healthcare settings,and age groups,with cumulative incidence rates ranging from 1.12 to 631.80 per 100,000 people annually[2].As the epidemiology of CDI continues to evolve and our understanding of the disease advances,reassessing its burden remains essential.The Global Burden of Disease,Injury,and Risk Factors Study(GBD 2021)database offers new insights into this issue.
